Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

253.04 +3.07 (+1.23%)
Official Closing Price Updated: 7:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report? ↗
J&J has more than 28 sources of blockbuster revenue. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
My 2 Favorite Dividend Kings to Buy Right Now ↗
They can help stabilize your portfolio in these otherwise volatile times. 
Via The Motley Fool
Topics Intellectual Property
News headline image
MarketBeat Week in Review – 07/13- 07/17 ↗
A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings. 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
Johnson & Johnson (NYSE:JNJ) Raises Full-Year Guidance After In-Line Q2 Results ↗
Via Chartmill
These dow jones stocks are moving in today's session ↗
Via Chartmill
Top dow jones movers in Friday's session ↗
Via Chartmill
News headline image
Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst ↗
The reasons why RBC Capital Markets maintains its stock rating. 
Via Benzinga
News headline image
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? ↗
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage. 
Via The Motley Fool
News headline image
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
From Johnson & Johnson
Via Business Wire
News headline image
DePuy Synthes Acquires Expanding Innovations™
From DePuy Synthes
Via Business Wire
News headline image
Full Transcript: Johnson & Johnson Q2 2026 Earnings Call ↗
Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
News headline image
Is Johnson & Johnson a Buy After Its Latest Earnings Report? ↗
Investors didn't seem to think so after the company published it. 
Via The Motley Fool
News headline image
Author’s Tranquility Press Announces a Powerful New Memoir of Faith, Survival, and Purpose
Via AB Newswire
What's going on in today's session: dow jones movers ↗
Via Chartmill
News headline image
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity ↗
Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch. 
Via MarketBeat
Topics Intellectual Property
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
News headline image
Johnson & Johnson Q2 Earnings Call Highlights ↗
Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook ↗
Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech. 
Via Benzinga
News headline image
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
From Johnson & Johnson
Via Business Wire
News headline image
Morgan Stanley, Johnson & Johnson And 3 Stocks To Watch Heading Into Wednesday ↗
Morgan Stanley, Pentair, Johnson & Johnson expected to release earnings, ASML posts strong results, Progressive to report 
Via Benzinga
Top dow jones movers in Tuesday's session ↗
Via Chartmill
News headline image
Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’ ↗
Johnson & Johnson stock trades near all-time highs. A strong Q2 report and the chart show more upside ahead. 
Via Benzinga
News headline image
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings ↗
Earnings report for JNJ expected on July 15, with analysts predicting $2.85/share & $25.06B revenue. Stock price target raised to $287/share. 
Via Benzinga
News headline image
This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy? ↗
The dividend looks secure. The share price is the harder call. 
Via The Motley Fool
Topics Lawsuit
News headline image
Stock Indexes Split as Chip Stocks Fall, Oil Surges ↗
Why are chip stocks collapsing while the Dow barely budges? Korean markets just had their worst day since the 2008 financial crisis, and the fallout is hitting semiconductors hard. 
Via The Motley Fool
Topics Artificial Intelligence Government Initial Public Offering
News headline image
3 Dividend Stocks Leading 2026's Rotation Into Value ↗
As investors flee this year's high flyers, a few dependable payers are catching the money. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors. ↗
Griffin is at the helm of the world's most profitable hedge fund. 
Via The Motley Fool
News headline image
This Dividend ETF Choice Could Shape Your Income Strategy Through 2026 ↗
VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth... 
Via MarketBeat
Topics Bonds ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.